Cavitation Technologies: revenue falls to zero, quarterly net loss narrows to $208K
Cavitation Technologies (CTi) reported zero revenue in its latest 10-Q quarter, with net loss narrowing to $208K from $258K, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Cavitation Technologies (CTi) reported zero revenue in its 10-Q quarterly filing, against $3K in the prior-year quarter. Its net loss narrowed to $208K from $258K, a 19.4% improvement. Diluted loss per share rounded to zero in both periods.
According to TradingView, the prior-year revenue came from renting a Nano Reactor. After a 2024 patent assignment transferred vegetable-oil refining technology to Desmet, which is expected to make reactors itself, CTi's sales to Desmet declined.
The company also updated its projects. Its water-treatment system in the Permian Basin has run for more than six months at a Texas remediation company, with further testing and customer outreach under way, and Hacienda Farms is trialing it. ABI expects initial Barmuze sales in the first half of 2027, Hydro-Plasma trials are underway, and Xyra is developing plasma applications for data centers and financial services.
why it matters
The company is small, and zero revenue makes this report marginal for the broad market. For investors in the stock, the pace of pilot projects and the timing of first sales matter more, and both still depend on trials and production readiness.
tags
instruments
sources
- Cavitation Technologies 2026: Revenue $0 Net income ($208K), EPS $0— 10-Q Summary — TradingView, 27 October 2026 at 18:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗